GeneDx Holdings Securities Fraud Class Action Result of Acquisition Performance Misrepresentations and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

Kahn Swick & Foti , LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until August 3, 2026 to file lead plaintiff applications in a securities class action lawsuit against GeneDx Holdings Corp. (NasdaqGS: WGS) (“GeneDx” or the “Company”), if they purchased or otherwise acquired the Company’s shares between April 16, 2025 and May 4, 2026, inclusive (the “Class Period”).

If you purchased shares of GeneDx as above and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-833-538-3616 or via email ( [email protected] ), or visit https://www.ksfcounsel.com/cases/nasdaqgs-wgs/ to learn more.

If you wish to serve as a lead plaintiff in this class action, you must petition the Court by August 3, 2026 .

GeneDx and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.

On May 4, 2026, the Company reported its financial results for the first quarter of fiscal year 2026, disclosing a drop in adjusted gross margin from 74% to 69%, that it had missed its revenue estimates for both its exome and genome lines, and lowered its guidance for full year revenue to $475 – $490 million, down from $540 – $550 million.

The Company also disclosed a $31.2 million impairment loss attributable to its prior acquisition of Fabric Genomics, an AI-driven genomic interpretation company, which the Company had touted as expected to expand its addressable market through multiple scalable revenue streams and transform static data into a recurring revenue-generating platform.

On this news, the price of GeneDx shares fell by $33.42 per share, or 49.2%.

The case is Basma v. GeneDx Holdings Corp., No. 26-cv-00880.